Cytosorbents price to sales ratio CTSO

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: 0.4×
10-year median: 6.7×
Against its 10-year history: 1st; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.3× to 24.1×
Peer median: 0.9×

Cytosorbents' price to sales ratio is 0.4× as of Oct 23, 2026.

That is below its ten-year median of 6.7×, lower than on 99% of days in the last ten years.

Over that time it ranged from 0.3× in Oct 2026 to 24.1× in Aug 2018.

The median for 3 medical instruments and supplies stocks of a similar size is 0.9×.

Price to sales ratio over time

median 6.7×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.4×	0.3×	1.1×
2025	1.4×	1.4×	1.9×
2024	1.4×	1.0×	2.3×
2023	1.3×	1.3×	4.6×
2022	1.9×	1.4×	3.8×
2021	4.1×	4.1×	13.5×
2020	9.4×	5.2×	14.4×
2019	5.3×	5.3×	12.7×
2018	11.7×	10.6×	24.1×
2017	13.7×	9.5×	18.5×
2016	16.9×	15.2×	33.3×
2015	36.2×	36.2×	80.6×
2014	61.4×	14.5×	61.4×
2013	14.3×	10.8×	42.9×
2012	39.8×	33.7×	44.1×

Against its peers

Companies in Medical - Instruments & Supplies nearest Cytosorbents' size, closest first, today.

Company	Price to sales ratio
CTSOCytosorbents	0.4×
NEPHNephros	1.9×
APTAlpha Pro Tech	0.9×
KEQUKewaunee Scientific	0.3×
Peer median	0.9×

Where Cytosorbents ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Cytosorbents

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.